VNDA

Fortrea Holdings Inc. (FTRE) is expected to report Q3 2026 earnings of $0.24 per share, representing 100% year-over-year growth, though revenues are projected to decline 4.4%. With a negative Earnings ESP of -10.35% and Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 2 of the last 4 quarters.

Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.